Gilead Presents Idelalisib Data Zacks.com The patients have not responded to treatments by Roche Holding AG's (RHHBY) Rituxan (rituximab) and alkylating-agent-containing chemotherapy. The company intends to present detailed data from the study shortly. Overall response rate (ORR) is the ... |
